TrialBlood2022

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.

John F Seymour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.